|
Proteome Sciences commercialises its discoveries through external partnering arrangements by way of out-licensing and strategic alliances.
Biomarkers
Novel protein biomarkers of disease identified from its internal research for diagnostic, prognostic or therapeutic applications are out-licensed to pharmaceutical and diagnostics companies for late stage product development and commercialisation.
Listed below are a selection of diseases where biomarkers have been discovered and are available for out-licensing:
Disease |
Application |
Discovery/Validation |
Licensed |
Stroke |
POC |
 |
|
|
Central Labs |
|
|
BSE |
Animals |
|
|
CJD/vCJD |
Blood Screening |
|
Mid term |
|
Clinical |
|
Mid term |
Alzheimer’s |
Biomarkers |
|
|
|
Target |
|
Near/mid term |
Organ Rejection |
Acute Coronary |
|
Mid term |
|
Chronic Coronary |
|
Mid term |
|
Renal |
|
Mid term |
Cancer |
Lung |
|
|
|
Breast |
|
Near/mid term |
|
Oesophagus |
|
Near/mid term |
|
Neuroblastoma |
|
Near/mid term |
Metabolic |
Type II Diabetes |
|
Mid/long term |
PS Biomarker Services
The powerful PS Biomarker Services technology platform has been specifically designed to provide solutions to many of the key problems and difficulties encountered in protein expression in complex human samples. Particular emphasis has been concentrated on:
| Membrane and nuclear proteins |
|
| Post translational modifications |
-
Phosphorylation/glycosylation |
| Blood plasma depletion |
|
| Chemical tagging |
-
PST®, qPST™, TMT® to reduce
data complexity |
| Early toxicity/mechanisms of toxicity |
|
| Drug efficiency and mode of action |
|
Proteome Sciences Biomarker Services offers strategic alliances and funded research projects to major pharmaceutical and diagnostics companies. These cover existing areas of disease, new and additional focuses and applications and MS assay development.
To view the PS Biomarker Services flyer click here.
Reagents
Proteome Sciences has developed the ‘Sensitizer® Family’ of
reagents with a common feature: these increase the number of peptides
and proteins that can be identified and quantified from complex protein
mixtures. Whilst the ‘Sensitizer®’ feature is common
to all the classes of molecules, the manner in which they achieve their
effect is slightly different in each case, giving each member of the
family a unique application.
These consist of:
Sensitizer® Tags
Sensitizer® |
- |
Increased sensitivity of signal detection
by MALDI-TOF by improved ionization of peptides and subsequent
improved protein identification. CombiSensitizer™ tags
unite peptide signal amplification with relative quantification. |
Protein Sequence Tags®
PST® |
- |
Increased number of protein identification
and relative quantifications by reduction of sample complexity. |
Quantitative Protein Sequence
Tags®
qPST™ |
- |
Isotopically labelled pairs of tags
provide relative protein quantification. |
Tandem Mass Tags®
TMT® |
- |
Isobaric multiplexing ability without
increasing complexity combined with accurate, sensitive protein
identification and quantification. |
Veri-Q |
- |
Reagents to detect levels of impurity
in synthetic oligonucleotides in RNA, RNAi, DNA, microarrays
and QC in synthetic oligonucleotide production. |
Some of these reagents are only provided through PS Biomarker Services strategic
alliances. Licenses can be obtained for the Veri-Q QC reagents/antibodies against
the protecting/de-protecting groups for applications in antisense
therapeutics and oligonucleotide diagnostics.
Site last updated: 3rd March, 2010
|
